Page 483 - Read Online

Page 8 of 9 Agdamag et al. Vessel Plus 2020;4:42 I http://dx.doi.org/10.20517/2574-1209.2020.60

24. Momtazi-Borojeni AA, Jaafari MR, Badiee A, Banach M, Sahebkar A. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse
model of atherosclerosis. BMC Med 2019;17:223.
25. Wu D, Zhou Y, Pan Y, et al. Vaccine against PCSK9 improved renal fibrosis by regulating fatty acid β-Oxidation. J Am Heart Assoc
2020;9:e014358.
26. Cholesterol treatment trialists’ (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis
of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
27. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-
analysis of statin trials. J Am Coll Cardiol 2014;64:485-94.
28. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of
heart failure: a report of the american college of cardiology/American heart association task force on clinical practice guidelines and the
heart failure society of America. J Am Coll Cardiol 2017;70:776-803.
29. Ponikowski P, Voors AA, Anker SD, et al; Authors/task force members, document reviewers. 2016 ESC guidelines for the diagnosis
and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the
european society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J
Heart Fail 2016;18:891-975.
30. Florkowski CM, Molyneux SL, George PM. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2008;358:1301.
31. Gissi-hf investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind,
placebo-controlled trial. Lancet 2008;372:1231-9.
32. Bayes-Genis A, Núñez J, Zannad F, et al. The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am
Coll Cardiol 2017;70:2128-36.
33. Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB
activation in THP-1-derived macrophages. Int J Mol Med 2012;30:931-8.
34. Stulak JM, Davis ME, Haglund N, et al. Adverse events in contemporary continuous-flow left ventricular assist devices: A multi-
institutional comparison shows significant differences. J Thorac Cardiovasc Surg 2016;151:177-89.
35. Goldstein DJ, Meyns B, Xie R, et al. Third annual report from the ISHLT mechanically assisted circulatory support registry: a comparison
of centrifugal and axial continuous-flow left ventricular assist devices. J Heart Lung Transplant 2019;38:352-63.
36. Mehra MR, Uriel N, Naka Y, et al; MOMENTUM 3 Investigators. A fully magnetically levitated left ventricular assist device-final report.
N Engl J Med 2019;380:1618-27.
37. Vieira JL, Pfeffer M, Claggett BL, et al. The impact of statin therapy on neurological events following left ventricular assist system
implantation in advanced heart failure. J Heart Lung Transplant 2020;39:582-92.
38. Costanzo MR, Dipchand A, Starling R, et al; International society of heart and lung transplantation guidelines. The international society
of heart and lung transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010;29:914-56.
39. Khush KK, Cherikh WS, Chambers DC, et al; International society for heart and lung transplantation. The international thoracic organ
transplant registry of the international society for heart and lung transplantation: thirty-fifth adult heart transplantation report-2018; focus
theme: multiorgan transplantation. J Heart Lung Transplant 2018;37:1155-68.
40. Lu WH, Palatnik K, Fishbein GA, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64
allograft hearts. J Heart Lung Transplant 2011;30:1044-50.
41. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006;99:801-15.
42. Lee F, Nair V, Chih S. Cardiac allograft vasculopathy: insights on pathogenesis and therapy. Clin Transplant 2020;34:e13794.
43. Lund LH, Edwards LB, Dipchand AI, et al; International society for heart and lung transplantation. The registry of the international
society for heart and lung transplantation: thirty-third adult heart transplantation report-2016; focus theme: primary diagnostic indications
for transplant. J Heart Lung Transplant 2016;35:1158-69.
44. Kühl M, Binner C, Jozwiak J, et al. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.
PLoS One 2019;14:e0210373.
45. Moayedi Y, Kozuszko S, Knowles JW, et al. Safety and efficacy of PCSK9 inhibitors after heart transplantation. Can J Cardiol
2019;35:104.e1-3.
46. Toth PP, Descamps O, Genest J, et al; PROFICIO investigators. Pooled safety analysis of evolocumab in over 6000 patients from double-
blind and open-label extension studies. Circulation 2017;135:1819-31.
47. Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the
PCSK9 pathway. Atherosclerosis 2013;228:18-28.
48. Simha V, Qin S, Shah P, et al. Sirolimus therapy is associated with elevation in circulating PCSK9 levels in cardiac transplant patients. J
Cardiovasc Transl Res 2017;10:9-15.
49. Warden BA, Kaufman T, Minnier J, Duell PB, Fazio S, Shapiro MD. Use of PCSK9 inhibitors in solid organ transplantation recipients.
JACC: Case Reports 2020;2:396-9.
50. Sandesara PB, Dhindsa D, Hirsh B, Jokhadar M, Cole RT, Sperling LS. PCSK9 inhibition in patients with heart transplantation: a case
series. J Clin Lipidol 2019;13:721-4.
51. Groba-Marco MDV, Del Castillo-García S, Barge-Caballero G, Barge-Caballero E, Couto-Mallón D, Crespo-Leiro MG. Treatment
of Hypercholesterolemia With PCSK9 inhibitors in heart transplant recipients. First experience in spain. Rev Esp Cardiol (Engl Ed)
2019;72:1084-6.
52. Jennings DL, Jackson R, Farr M. PCSK9 inhibitor use in heart transplant recipients: a case series and review of the literature.